Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia.
about
Epigenetic regulation of human alpha1d-adrenergic receptor gene expression: a role for DNA methylation in Sp1-dependent regulationHypothesis to explain poor outcomes in the ALLHAT and V-HeFT trials: decreased expression of heat shock proteinsEffects of tamsulosin on premature ejaculation in men with benign prostatic hyperplasiaPatient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.Current concepts in the pharmacotherapy of benign prostatic hyperplasia.Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life.Ejaculatory disorders and sexual function.Selecting therapy for maintaining sexual function in patients with benign prostatic hyperplasia.Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice.Impact of medical treatments for benign prostatic hyperplasia on sexual function.Management of bladder, prostatic and pelvic floor disorders.Effect of tamsulosin on ejaculatory function in BPH/LUTS.Tamsulosin MR and OCAS (modified release and oral controlled absorption system): current therapeutic uses.Effects of low-dose tamsulosin on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.Measurement of benign prostatic hyperplasia treatment effects on male sexual function.Efficacy of Dose Escalation of Tamsulosin for the Treatment of Lower Urinary Tract Symptoms.A randomised, double-blind study comparing the efficacy and tolerability of controlled-release doxazosin and tamsulosin in the treatment of benign prostatic hyperplasia in Brazil.Long-term treatment outcome of tamsulosin for benign prostatic hyperplasia.Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH.Prostatic urethral angle might be a predictor of treatment efficacy of α-blockers in men with lower urinary tract symptoms.The role of urethral pressure profile on treating premature ejaculation by tamsulosin.Comparison of tamsulosin and finasteride for lower urinary tract symptoms associated with benign prostatic hyperplasia in Korean patients.Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH.Effects of Silodosin and Tamsulosin on the Seminal Vesicle Contractile Response.The effect of first dose of tamsulosin on flow rate and its predictive ability on the improvement of LUTS in men with BPH in the mid-term.Superselective α-adrenergic blockers versus transurethral resection of the prostate: a prospective comparison of health-related quality of life outcome after treating patients with benign prostatic hyperplasia.Comparison between tamsulosin and alfuzosin on the expulsion phase of ejaculation in rats.Does this treatment work for me? The patient's role in assessing medical care.Evaluation of patient outcome after discontinuation of alfuzosin treatment for benign prostatic hyperplasia: a multicentre, prospective study.Botulinum neurotoxin type A for the treatment of benign prostatic hyperplasia: randomized study comparing two doses.
P2860
Q24646956-14D4751F-A37E-4B39-807C-8A1D1AEA4DA0Q24799234-44D1CC45-8CFC-4B24-920B-952304F16380Q34198858-8AE653A9-1983-407B-A8B4-61960CBE4303Q34639437-7126613F-1AF5-4BB8-B895-0F41398DE9A1Q35020534-90F73495-0A78-4864-8FA9-B5BB2FC088F9Q35204840-5CA1BDC1-34B6-49EB-A240-6E8372A5CD6BQ36126882-2272489D-91D9-4B89-9FE6-694A08B2BE13Q36206605-63E8132A-B529-4475-96AA-66DD92E0DB32Q36371582-15922E33-3BC6-462E-B2DC-C8EA6E3C3AACQ36409144-A92FF690-DD6D-4321-AF5E-E3C71CE38599Q36511604-E59E0370-89CE-42D7-9C49-1DE63460AB26Q37085210-644A26C1-F3B8-47D8-B661-9B49F0101C81Q37111860-CCB610B9-D294-4BDF-8B03-BD20ECA40F9BQ37251847-AEEF858D-24A4-49C4-8812-1EC0F0D7344EQ37523227-445C1A6D-84C4-4F80-8C22-4F0E8AE7D874Q38463030-0291FF83-DC62-4C0F-AD92-5D8F3D5AC448Q38785523-88659A81-8C7E-482C-876D-37C59D8BE948Q39375083-589817DA-9710-4063-9681-875814062EE1Q41922883-A1D89ED8-CCD5-46F8-A14C-25412E5CB22EQ42051597-7C74EDC6-FA2D-41F5-BA74-79250E23AED2Q42970272-DB7B71E8-ECF4-4C38-8994-66D795676FB9Q44277081-25773ECB-3179-4585-8BB4-7CCDF9E90C9AQ46350332-0483DA70-5A83-4478-A7FF-D397418AF095Q46637526-02B8FC37-826E-4FD6-BD73-01E4756DCA58Q48323154-62386759-56B9-4EFF-9842-5F2504DBC1E8Q48392670-5E206ECE-AEA8-49F1-A957-C80704BD106FQ48676607-FEBE0948-9DAC-4D5E-8A8D-C4809F2CC122Q49428513-91B23839-CF9F-4704-A0AA-FEA31D0010CBQ53105128-B62587FF-2DA5-4D63-A88C-37C788ABAA02Q53123387-54A7253A-A885-486A-87BF-4FE9BD9BFAE2
P2860
Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Long-term, open-label, phase I ...... benign prostatic hyperplasia.
@en
Long-term, open-label, phase I ...... benign prostatic hyperplasia.
@nl
type
label
Long-term, open-label, phase I ...... benign prostatic hyperplasia.
@en
Long-term, open-label, phase I ...... benign prostatic hyperplasia.
@nl
prefLabel
Long-term, open-label, phase I ...... benign prostatic hyperplasia.
@en
Long-term, open-label, phase I ...... benign prostatic hyperplasia.
@nl
P1433
P1476
Long-term, open-label, phase I ...... benign prostatic hyperplasia.
@en
P2093
P304
P356
10.1016/S0090-4295(00)01042-6
P407
P577
2001-03-01T00:00:00Z